Investments in next-generation manufacturing facilities are unlocking scale, speed, and quality for cell and gene therapies, propelling North …
Investments in next-generation manufacturing facilities are unlocking scale, speed, and quality for cell and gene therapies, propelling North …
European regulatory reforms are accelerating approvals for novel rare disease treatments, attracting global investment and expanding patient access.
Asia-Pacific biopharma conferences in early 2025 are forging strategic partnerships, launching research initiatives, and accelerating drug development.
An established diagnostics firm gains critical funding to advance its wearable glucose monitoring technology and drive a strategic …
The FDA has approved GSK’s MenABCWY vaccine—the first pentavalent conjugate capable of protecting against five key meningococcal serogroups—marking …
New clinical-stage anti-obesity therapies began breaking ground—designed not just to shed pounds, but to retain muscle, offering a …
Uvax Bio elevated Chief Business Officer Kevin O’Neill to Interim CEO following the departure of Ji Li, Ph.D., …
Johnson & Johnson discontinues three neuroscience programs—including the sleep-focused seltorexant—realigning its R&D priorities and signaling a strategic course …
At the 2025 ASCO Gastrointestinal Cancers Symposium, ALX Oncology presents promising Phase II data showing that evorpacept, a …
The European Medicines Agency approves GSK’s PD-1 inhibitor, Jemperli, in combination with chemotherapy as a first-line therapy for …
Already a subscriber? Log in